Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

NCT ID: NCT03143998

Last Updated: 2017-11-09

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-12
• Study Completion Date: 2019-01-12

Brief Summary

This is a non-randomized, open-label study of a fixed dose combination (FDC) of elbasvir (50 mg) and grazoprevir (100 mg) (EBR/GZR or MK-5172A) in participants with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection with advanced fibrosis with and without human immunodeficiency virus (HIV) co-infection. All participants will be either HCV treatment naïve (TN) or treatment experienced (TE).

Conditions

Hepatitis C

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HCV GT1a TN

Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.

Group Type: EXPERIMENTAL

MK-5172A

Intervention Type: DRUG

A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

HCV GT1a TE

Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.

Group Type: EXPERIMENTAL

MK-5172A

Intervention Type: DRUG

A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

HCV GT1b TN

Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.

Group Type: EXPERIMENTAL

MK-5172A

Intervention Type: DRUG

A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

HCV GT1b TE

Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.

Group Type: EXPERIMENTAL

MK-5172A

Intervention Type: DRUG

A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

Interventions

MK-5172A

A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.

Intervention Type: DRUG

Other Intervention Names

ZEPATIER®

Eligibility Criteria

Inclusion Criteria

• Adult (≥ 18 years of age) male and female participants with chronic HCV GT1 infection who reside in Brazil
• HCV RNA (≥ 10,000 IU/mL in peripheral blood) at the time of screening
• Has documented chronic HCV GT1 (1a; 1b) infection (with no evidence of non-typeable or mixed genotype) infection.

• positive for anti HCV antibody, HCV RNA, or HCV GT1 at least 6 months before screening, or
• positive for anti-HCV antibody or HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed before enrollment with evidence of chronic hepatitis C (CHC) disease, such as the presence of fibrosis)
• Is otherwise healthy as determined by the medical history, physical examination, and clinical laboratory measurements at the time of screening
• Has a history of advanced fibrosis (F3 or F4) as follows:

• F4: FibroSure®/APRI + FibroTest®
• Liver biopsy result of METAVIR stage 3 or 4 fibrosis (or its grading system equivalency to advanced fibrosis)
• FibroScan® result > 9.5 kPa (F3 or F4)
• Has liver imaging within 6 months of Day 1 (start of treatment) with no evidence of hepatocellular carcinoma (HCC)
• Is TN or TE
• Is a male, is a female who is not of reproductive potential, or is a female of reproductive potential who agrees to avoid becoming pregnant from Day 1 (start of treatment) through 14 days after the last dose of study drug (or longer if dictated by local regulations)
• For HIV-infected participants, has HIV-1 infection documented prior to screening, and is either not currently on antiretroviral therapy (ART) and has no plans to initiate ART or has well-controlled HIV on ART as per study criteria

Exclusion Criteria

• Has prior treatment with direct acting antiviral (DAA) therapy with the exception of boceprevir, telaprevir, and simeprevir
• Has evidence of decompensated liver disease as manifested by the presence of or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy, or other signs or symptoms of active advanced liver disease
• Is classified as Child-Pugh B or C or has a Child-Pugh-Turcotte score > 6
• Is hepatitis B surface antigen (HBsAg) positive at screening
• Is under evaluation for HCC or other active or suspected malignancy
• Is currently participating or has participated in a study with an investigational compound within 1 year of signing informed consent and is not willing to refrain from participating in another such study during the course of this study
• Has clinically-relevant drug or alcohol abuse within 12 months of screening
• Is a female and is pregnant or breastfeeding, or expecting to conceive or donate eggs from Day 1 (start of treatment) through 14 days after the last dose of study drug or longer if dictated by local regulations; or is a male participant who is expecting to donate sperm from Day 1 (start of treatment) through 14 days after the last dose of study drug or longer if dictated by local regulations
• Has any clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol or any medical/surgical conditions that may result in a need for hospitalization during the period of the study; or is currently under evaluation for a potentially clinically-significant illness (other than HCV)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Other Identifiers

5172-089

Identifier Type: -

Identifier Source: org_study_id